CONMED Corp. 10-Q Summary: Quarter Ended September 27, 1996
Business Context and Reporting Period
CONMED Corporation, a developer, manufacturer, and marketer of disposable medical products and related devices, filed its Form 10-Q for the quarter ended September 27, 1996. The company operates primarily in the medical technology sector. As of October 31, 1996, there were 14,944,693 shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended Sept 27, 1996 | Nine Months Ended Sept 27, 1996 |
|---|---|---|
| Net Sales | $31,432,000 | $92,422,000 |
| Net Income | $4,033,000 | $11,529,000 |
| Earnings Per Share | $0.27 | $0.81 |
| Gross Margin | ~47.5% | 47.9% |
| Operating Cash Flow (9 months) | N/A | $17,179,000 |
| Cash and Equivalents (End of Period) | $13,978,000 | $13,978,000 |
| Total Debt | $0 | $0 |
Note: The company eliminated all indebtedness in March 1996 using proceeds from an equity offering. Total assets increased to $164,953,000, driven largely by goodwill from acquisitions.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 19.7% in the quarter and 29% for the nine-month period compared to 1995. This growth is primarily attributed to the acquisition of New Dimensions in Medicine, Inc. (NDM) in February 1996, as well as prior acquisitions of Birtcher Medical Systems and Master Medical Corporation.
- Profitability: Net income rose 39.6% for the quarter and 52.8% for the nine-month period. Gross margin improved to 47.9% for the nine months (from 47.2% in 1995) due to economies of scale and manufacturing efficiencies, partially offset by lower margins on the NDM product line.
- Debt Elimination: Interest expense turned to interest income in the third quarter. The company repaid all debt (approximately $65 million peak borrowing) in March 1996 following a public stock offering.
- Balance Sheet: Cash and cash equivalents surged from $1,539,000 at year-end 1995 to $13,978,000. Goodwill increased significantly to $60,696,000 due to recent acquisitions.
Outlook, Risks, and Management Commentary
- Acquisition Integration: Management notes that the NDM acquisition is being accounted for using the purchase method, with purchase price allocation based on preliminary estimates subject to potential re-allocation in the next six months.
- Liquidity: The company maintains a $60,000,000 secured revolving line of credit expiring in March 2001. Management believes current cash resources and operating cash flows are sufficient for working capital and capital expenditures.
- R&D Focus: Research and development expenses increased to $861,000 for the quarter, reflecting activity in developing minimally-invasive surgical products.
- Operational Efficiency: Gross margins benefited from the relocation of the ECG manufacturing facility from Massachusetts to New York in late 1995.
Investor Verification Checklist
- Verify the final purchase price allocation for the New Dimensions in Medicine (NDM) acquisition, as preliminary estimates may change.
- Monitor the integration of NDM's product line to ensure gross margin expectations are met despite the noted lower margins of that specific line.
- Confirm the utilization of the $60 million credit facility and the company's ability to maintain defined cash flow performance ratios.
- Review the impact of the March 1996 stock offering on future dilution and share count growth.
- Assess the sustainability of operating cash flows given the significant increase in accounts receivable ($26.2 million) and inventory ($23.0 million).